Drug Profile

MORF 057

Alternative Names: LY-4268989; MORF-057; MR-beta7

Latest Information Update: 13 May 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Harvard Medical School; Morphic Therapeutic
Developer Eli Lilly and Company
Class Anti-inflammatories; Small molecules
Mechanism of Action Integrin alpha4beta7 antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II Crohn's disease; Ulcerative colitis

Most Recent Events

09 May 2025 Eli Lilly and Company plans a phase I trial in Healthy volunteers in USA (PO) in May 2025 (NCT06964776)
19 Feb 2025 Morphic Therapeutic completes the phase-IIb EMERALD-1 trial for Ulcerative colitis in USA and Poland (PO, Capsule) (NCT05291689)
16 Aug 2024 Morphic Therapeutic has been acquired and merged into Eli Lilly and Company

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com